Chafic Karam, MD
Neurology · Portland, ORNPI 1326200163
Payments from drug & device makers
Across 610 payments — averaging $4538.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Argenx US, Inc.$1.2M
- Sanofi$398K
- Sanofi US Services Inc.$231K
- UCB SA$214K
- Akcea Therapeutics, Inc.$150K
- Alnylam Pharmaceuticals Inc.$138K
- plus $464K from 22 others
Across 2 payments — averaging $600.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$1K
What the payments were for
- Consulting fees$425,33658%
- Speaking & faculty fees$219,89130%
- Travel & lodging$70,97210%
- Food & beverage$10,8021%
- Education$1970%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Argenx US, Inc. | 102 | $1,173,223 |
| Sanofi | 90 | $398,158 |
| Sanofi US Services Inc. | 9 | $230,686 |
| UCB SA | 7 | $214,143 |
| Akcea Therapeutics, Inc. | 84 | $150,066 |
| Alnylam Pharmaceuticals Inc. | 52 | $138,137 |
| Orion Corporation | 22 | $105,029 |
| Takeda Pharmaceuticals U.S.A., Inc. | 101 | $91,962 |
| Astrazeneca UK Limited | 9 | $55,966 |
| Ionis Pharmaceuticals, Inc. | 1 | $38,788 |
| AstraZeneca(2 entities) | 36 | $34,685 |
| CSL Behring | 31 | $32,351 |
| Eli Lilly | 2 | $21,209 |
| Genentech, Inc. | 4 | $18,033 |
| Spark Therapeutics, Inc. | 7 | $16,175 |
| UCB, Inc. | 15 | $10,216 |
| Johnson & Johnson(2 entities) | 6 | $8,561 |
| Vertex | 15 | $7,974 |
| Octapharma USA, Inc. | 4 | $5,775 |
| Amgen | 2 | $3,400 |
| Amicus Therapeutics, Inc. | 2 | $2,983 |
| Janssen Scientific Affairs, LLC | 1 | $2,500 |
| Biogen | 1 | $2,100 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $2,000 |
| Swedish Orphan Biovitrum AB | 1 | $1,640 |
| Novo Nordisk AS | 1 | $1,500 |
| Catalyst Pharmaceuticals, Inc. | 2 | $1,370 |
| Sanofi-aventis U.S. LLC | 2 | $108 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,768,739 in reported general payments places this provider in the 95th percentile of 228 neurology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AmvuttraVutrisiran Sodium | 11 | $1,235,802 |
| WainuaEplontersen Sodium | 21 | $875,769 |
| OnpattroPatisiran Sodium,lipid Complex | 17 | $485,072 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $328,059 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 12 | $300,089 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 19 | $272,306 |
| Gabapentin | 74 | $2,236 |
| Mycophenolate Mofetil | 14 | $514 |
| Nortriptyline Hcl | 19 | $437 |
| Duloxetine Hcl | 26 | $305 |
| Sodium Chloride0.9 % Sodium Chloride | 20 | $35 |
| Dexamethasone | 16 | $20 |
| FamotidineFamotidine/Pf | 16 | $17 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Alnylam Pharmaceuticals Inc.Amvuttra, Onpattro | $138,137 | $1,720,87428 claims |
| AstraZenecaWainua | $34,685 | $875,76921 claims |
| CSL BehringHizentra, Privigen | $32,351 | $600,36532 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $91,962 | $300,08912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 228 neurology providers in Oregon.
Other neurology in Portland
- Stanley CohanPortland$3.9M
- Kyle SmootPortland$3.2M
- Aimee PiercePortland$3M
- Prakash AmbadyPortland$2.7M
- Michael MegaPortland$2.5M
- Jeffrey KayePortland$1.5M
- Nizar ChahinPortland$1.4M
- Matthew BrodskyPortland$1.3M
- Wayne ClarkPortland$741K
- Richard RosenbaumPortland$589K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.